Evidence map›Paper›PMID 11193828›Full record

ArticleAnnals of the New York Academy of Sciences2000

Role of PACAP1 receptor in regulation of ECL cells and gastric acid secretion by pituitary adenylate cyclase activating peptide.

J R Pisegna, G V Ohning, C Athmann, N Zeng, J H Walsh, G Sachs

Open access · greenAbstract read
In one paragraph

Article in Annals of the New York Academy of Sciences, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

J R PisegnaCURE: VA/UCLA Digestive Diseases Research Center, West LA VA Medical Center, Department of Physiology and Medicine, California, USA. jpisegna@ucla.edu
G V Ohning
C Athmann
N Zeng
J H Walsh
G Sachs
West Los Angeles College · USUniversity of California, Los Angeles · USVA Greater Los Angeles Healthcare System · US

Funding

Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
HORMONAL STIMULATION &INHIBITION OF GASTRIC SECRETIONR01DK017294 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1986 to 2003
$1.7M
GASTRIC ACID SECRETIONR01DK040615 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SACHS, GEORGE · 1988 to 1992
–
LOCALIZATION/SIGNAL TRANSDUCTIONR03DK052274 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PISEGNA, JOSEPH R · 1996 to 1997
–
HORMONAL STIMULATION AND INHIBITION OF GASTRIC SECRETIONR37DK017294 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WALSH, JOHN H · 1987 to 1994
–
BLRD VA I01 BX004560NIDDK NIH HHS DK17294NIDDK NIH HHS DK40615NIDDK NIH HHS DK41301NIDDK NIH HHS DK 52274-01NIDDK NIH HHS P30 DK041301RRD VA I01 RX000194
6 · The paper itself

Abstract

We previously reported that PAC1 is expressed on ECL cells resulting in stimulation of [Ca2+]i, histamine and acid secretion. The study reported here characterized the signaling by PAC1 on ECL cells; determined the effects of PACAP on the gastric acid secretion in vivo, and determined the effects of chronic administration of PACAP-27 on ECL cell proliferation. PACAP-27 dose dependently stimulated ECL cell Ca2+ and AC with detectable stimulation at 1 nM and maximal stimulation at 100 nM (six-fold). In rats PACAP-27 administration (10 pmol/kg/h) increased the rate of gastric acid secretion when an antisomatostatin antibody was co-administered. Chronic administration of PACAP (10 pmol/h for seven days) via osmotic pump resulted in a more than twofold increase in BrdU incorporation into ECL cells. PACAP acting at the PAC1 results in dual signaling responses to both [Ca2+]i. AC in ECL cells stimulates gastric acid secretion via the actions of histamine acting at the parietal cell and in whole animals leads to proliferation of ECL cells when administered chronically.

Indexed as

Adenylyl CyclasesAnimalsCell DivisionEnterochromaffin-like CellsGastric AcidImmunohistochemistryIn Vitro TechniquesNeuropeptidesPituitary Adenylate Cyclase-Activating PolypeptideRatsRats, Sprague-DawleyReceptors, Pituitary Adenylate Cyclase-Activating PolypeptideReceptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type IReceptors, Pituitary HormoneAdcyap1 protein, ratAdcyap1r1 protein, ratAdenylyl CyclasesNeuropeptidesPituitary Adenylate Cyclase-Activating PolypeptideReceptors, Pituitary Adenylate Cyclase-Activating PolypeptideReceptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type IReceptors, Pituitary Hormone

Identifiers

PMID11193828
PMCPMC6736551
OpenAlexW1995233452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.